COVID-19 vaccination in haematology patients: an Australian and New Zealand consensus position statement

Georgia McCaughan; Pietro Di Ciaccio; Michelle Ananda-Rajah; Nicole Gilroy; Raina MacIntyre; Benjamin Teh; Robert Weinkove; Jennifer Curnow; Jeff Szer; Anoop K. Enjeti; David M. Ross; Stephen Mulligan; Judith Trotman; Michael Dickinson; Hang Quach; Phillip Choi; Mark N. Polizzotto; Constantine S. Tam; P. Joy Ho; Matthew Ku; Gareth Gregory; Shane Gangatharan; Greg Hapgood; Tara Cochrane; Chan Cheah; Simon Gibbs; Andrew Wei; Anna Johnston; Matthew Greenwood; H. Miles Prince; Maya Latimer; Leanne Berkahn; Joel Wight; Tasman Armytage; Nada Hamad

doi:10.1111/imj.15247

COVID-19 vaccination in haematology patients: an Australian and New Zealand consensus position statement

Georgia McCaughan, Pietro Di Ciaccio, Michelle Ananda-Rajah, Nicole Gilroy, Raina MacIntyre, Benjamin Teh, Robert Weinkove, Jennifer Curnow, Jeff Szer, Anoop K. Enjeti, David M. Ross, Stephen Mulligan, Judith Trotman, Michael Dickinson, Hang Quach, Phillip Choi, Mark N. Polizzotto, Constantine S. Tam, P. Joy Ho, Matthew KuGareth Gregory, Shane Gangatharan, Greg Hapgood, Tara Cochrane, Chan Cheah, Simon Gibbs, Andrew Wei, Anna Johnston, Matthew Greenwood, H. Miles Prince, Maya Latimer, Leanne Berkahn, Joel Wight, Tasman Armytage, Nada Hamad

Research output: Contribution to journal › Article › peer-review

13 Citations (Scopus)

Abstract

Australia and New Zealand have achieved excellent community control of COVID-19 infection. In light of the imminent COVID-19 vaccination roll out in both countries, representatives from the Haematology Society of Australia and New Zealand and infectious diseases specialists have collaborated on this consensus position statement regarding COVID-19 vaccination in patients with haematological disorders. It is our recommendation that patients with haematological malignancies, and some benign haematological disorders, should have expedited access to high-efficacy COVID-19 vaccines, given that these patients are at high risk of morbidity and mortality from COVID-19 infection. Vaccination should not replace other public health measures in these patients, given that the effectiveness of COVID-19 vaccination, specifically in patients with haematological malignancies, is not known. Given the limited available data, prospective collection of safety and efficacy data of COVID-19 vaccination in this patient group is a priority.

Original language	English
Pages (from-to)	763-768
Number of pages	6
Journal	Internal Medicine Journal
Volume	51
Issue number	5
DOIs	https://doi.org/10.1111/imj.15247
Publication status	Published - May 2021
Externally published	Yes

Keywords

COVID-19
haematology
leukaemia
lymphoma
plasma cell
vaccination

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1111/imj.15247Licence: In Copyright

Cite this

McCaughan, G., Di Ciaccio, P., Ananda-Rajah, M., Gilroy, N., MacIntyre, R., Teh, B., Weinkove, R., Curnow, J., Szer, J., Enjeti, A. K., Ross, D. M., Mulligan, S., Trotman, J., Dickinson, M., Quach, H., Choi, P., Polizzotto, M. N., Tam, C. S., Ho, P. J., ... Hamad, N. (2021). COVID-19 vaccination in haematology patients: an Australian and New Zealand consensus position statement. Internal Medicine Journal, 51(5), 763-768. https://doi.org/10.1111/imj.15247

@article{fdfdc585684249ea9bf211707963f8db,

title = "COVID-19 vaccination in haematology patients: an Australian and New Zealand consensus position statement",

abstract = "Australia and New Zealand have achieved excellent community control of COVID-19 infection. In light of the imminent COVID-19 vaccination roll out in both countries, representatives from the Haematology Society of Australia and New Zealand and infectious diseases specialists have collaborated on this consensus position statement regarding COVID-19 vaccination in patients with haematological disorders. It is our recommendation that patients with haematological malignancies, and some benign haematological disorders, should have expedited access to high-efficacy COVID-19 vaccines, given that these patients are at high risk of morbidity and mortality from COVID-19 infection. Vaccination should not replace other public health measures in these patients, given that the effectiveness of COVID-19 vaccination, specifically in patients with haematological malignancies, is not known. Given the limited available data, prospective collection of safety and efficacy data of COVID-19 vaccination in this patient group is a priority.",

keywords = "COVID-19, haematology, leukaemia, lymphoma, plasma cell, vaccination",

author = "Georgia McCaughan and {Di Ciaccio}, Pietro and Michelle Ananda-Rajah and Nicole Gilroy and Raina MacIntyre and Benjamin Teh and Robert Weinkove and Jennifer Curnow and Jeff Szer and Enjeti, {Anoop K.} and Ross, {David M.} and Stephen Mulligan and Judith Trotman and Michael Dickinson and Hang Quach and Phillip Choi and Polizzotto, {Mark N.} and Tam, {Constantine S.} and Ho, {P. Joy} and Matthew Ku and Gareth Gregory and Shane Gangatharan and Greg Hapgood and Tara Cochrane and Chan Cheah and Simon Gibbs and Andrew Wei and Anna Johnston and Matthew Greenwood and Prince, {H. Miles} and Maya Latimer and Leanne Berkahn and Joel Wight and Tasman Armytage and Nada Hamad",

year = "2021",

month = may,

doi = "10.1111/imj.15247",

language = "English",

volume = "51",

pages = "763--768",

journal = "Internal Medicine Journal",

issn = "1444-0903",

publisher = "John Wiley & Sons, Inc",

number = "5",

}

McCaughan, G, Di Ciaccio, P, Ananda-Rajah, M, Gilroy, N, MacIntyre, R, Teh, B, Weinkove, R, Curnow, J, Szer, J, Enjeti, AK, Ross, DM, Mulligan, S, Trotman, J, Dickinson, M, Quach, H, Choi, P, Polizzotto, MN, Tam, CS, Ho, PJ, Ku, M, Gregory, G, Gangatharan, S, Hapgood, G, Cochrane, T, Cheah, C, Gibbs, S, Wei, A, Johnston, A, Greenwood, M, Prince, HM, Latimer, M, Berkahn, L, Wight, J, Armytage, T & Hamad, N 2021, 'COVID-19 vaccination in haematology patients: an Australian and New Zealand consensus position statement', Internal Medicine Journal, vol. 51, no. 5, pp. 763-768. https://doi.org/10.1111/imj.15247

TY - JOUR

T1 - COVID-19 vaccination in haematology patients

T2 - an Australian and New Zealand consensus position statement

AU - McCaughan, Georgia

AU - Di Ciaccio, Pietro

AU - Ananda-Rajah, Michelle

AU - Gilroy, Nicole

AU - MacIntyre, Raina

AU - Teh, Benjamin

AU - Weinkove, Robert

AU - Curnow, Jennifer

AU - Szer, Jeff

AU - Enjeti, Anoop K.

AU - Ross, David M.

AU - Mulligan, Stephen

AU - Trotman, Judith

AU - Dickinson, Michael

AU - Quach, Hang

AU - Choi, Phillip

AU - Polizzotto, Mark N.

AU - Tam, Constantine S.

AU - Ho, P. Joy

AU - Ku, Matthew

AU - Gregory, Gareth

AU - Gangatharan, Shane

AU - Hapgood, Greg

AU - Cochrane, Tara

AU - Cheah, Chan

AU - Gibbs, Simon

AU - Wei, Andrew

AU - Johnston, Anna

AU - Greenwood, Matthew

AU - Prince, H. Miles

AU - Latimer, Maya

AU - Berkahn, Leanne

AU - Wight, Joel

AU - Armytage, Tasman

AU - Hamad, Nada

PY - 2021/5

Y1 - 2021/5

N2 - Australia and New Zealand have achieved excellent community control of COVID-19 infection. In light of the imminent COVID-19 vaccination roll out in both countries, representatives from the Haematology Society of Australia and New Zealand and infectious diseases specialists have collaborated on this consensus position statement regarding COVID-19 vaccination in patients with haematological disorders. It is our recommendation that patients with haematological malignancies, and some benign haematological disorders, should have expedited access to high-efficacy COVID-19 vaccines, given that these patients are at high risk of morbidity and mortality from COVID-19 infection. Vaccination should not replace other public health measures in these patients, given that the effectiveness of COVID-19 vaccination, specifically in patients with haematological malignancies, is not known. Given the limited available data, prospective collection of safety and efficacy data of COVID-19 vaccination in this patient group is a priority.

AB - Australia and New Zealand have achieved excellent community control of COVID-19 infection. In light of the imminent COVID-19 vaccination roll out in both countries, representatives from the Haematology Society of Australia and New Zealand and infectious diseases specialists have collaborated on this consensus position statement regarding COVID-19 vaccination in patients with haematological disorders. It is our recommendation that patients with haematological malignancies, and some benign haematological disorders, should have expedited access to high-efficacy COVID-19 vaccines, given that these patients are at high risk of morbidity and mortality from COVID-19 infection. Vaccination should not replace other public health measures in these patients, given that the effectiveness of COVID-19 vaccination, specifically in patients with haematological malignancies, is not known. Given the limited available data, prospective collection of safety and efficacy data of COVID-19 vaccination in this patient group is a priority.

KW - COVID-19

KW - haematology

KW - leukaemia

KW - lymphoma

KW - plasma cell

KW - vaccination

UR - http://www.scopus.com/inward/record.url?scp=85107017237&partnerID=8YFLogxK

U2 - 10.1111/imj.15247

DO - 10.1111/imj.15247

M3 - Article

C2 - 34047035

AN - SCOPUS:85107017237

SN - 1444-0903

VL - 51

SP - 763

EP - 768

JO - Internal Medicine Journal

JF - Internal Medicine Journal

IS - 5

ER -

COVID-19 vaccination in haematology patients: an Australian and New Zealand consensus position statement

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this